Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma
- Novel iodine radiolabelled PARP inhibitor (rPARPi) entering clinical development in Phase 1 trial to assess safety and early efficacy
- Dose escalation study followed by expansion cohorts in recurrent glioblastoma with potential to move into primary glioblastoma
Berlin, Germany, 25 July 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it has commenced a Phase 1 first-in-human clinical trial (CITADEL-123) of 123I-ATT001, its Iodine-123 labelled PARP inhibitor, in patients with recurrent glioblastoma.
